Currently Viewing:
The Academy of Managed Care Pharmacy (AMCP) 2018
Currently Reading
Dr Somali Burgess on Translating Patient-Reported Outcomes Into Clinical, Pharmaceutical Decisions
June 11, 2018
Drug Approvals That Dr Aimee Tharaldson Is Keeping an Eye on for 2019
May 27, 2018
Dr Robert Navarro on Pharma Implementing Value, Best Practices for Value-Based Contracts
May 25, 2018
Dr Ashley Pappas Discusses Collaboration Between Academic Centers and Payers
May 24, 2018
Dr Calvin Knowlton on Innovative Practices in Enhanced Medication Therapy Management
May 20, 2018
Dr Tina Joseph Outlines Pharmacists' Role in Managing Chronic Diseases, Value-Based Care Models
May 19, 2018
Brian Litten Outlines Challenges With Adopting Medication Therapy Management Services
May 17, 2018
Dr Kimberly Lenz: Identifying Patients Most at Risk For Substance Abuse
May 13, 2018
Dr Robert Navarro Foresees Unintended Consequences From Shift to Value-Based Care
May 12, 2018
The Rise of Orphan Drugs for Rare Diseases
May 07, 2018
Dr Calvin Knowlton Outlines Benefits Seen From Enhanced Medication Therapy Management
May 06, 2018
Dr Aimee Tharaldson on Recently Approved Specialty Drugs, Upcoming Approvals to Watch
May 05, 2018
Hemophilia: Treatment Landscape, Costs, and Disease Management
April 26, 2018
Navigating the Rocky Waters to Value-Based Healthcare
April 26, 2018
Dr Tina Joseph Discusses Collaborative Practice Agreements Between Pharmacists, Physicians
April 26, 2018
Dr Somali Burgess on the Role of Patient-Reported Outcomes in Managed Care Pharmacy
April 26, 2018
Cardiologist Talks About Value of Monoclonal Antibody Evolocumab
April 26, 2018
Market Access Teams Face New Challenges in Pharma
April 25, 2018
Migraines in the US Are More Than Just a Pain Problem
April 25, 2018

Dr Somali Burgess on Translating Patient-Reported Outcomes Into Clinical, Pharmaceutical Decisions

Somali Burgess, PhD, senior director, Xcenda, discusses how patient-reported outcomes (PROs) help advance patient care and challenges with translating PROs into clinical and pharmaceutical decisions.


Somali Burgess, PhD, senior director, Xcenda, discusses how patient-reported outcomes (PROs) help advance patient care and challenges with translating PROs into clinical and pharmaceutical decisions.

Transcript

How does the incorporation of patient-reported outcomes help advance patient engagement and care?

I describe something called the 3 pillars, and the first pillar represents the registration, 1 represents reimbursement, and 1 represents brand. So, if you look at registration, patient-reported outcome (PRO) measures are included in clinical studies for registration, and so that is a direct benefit to the patient once that drug has been approved.

With reimbursement, formulary decisions are being made based on PRO data, so once that drug is put on the formulary based on that PRO data, or it’s being reimbursed, that’s another benefit to the patient because a drug is only as good as its reimbursement policy.

With the third pillar, which is brand, while it may not directly impact or prove beneficial to a patient, it is in an indirect way benefitting the patient because you do real-world studies. So, perspective studies and collecting real-world data, which is showing the burden of illness, or its showing what is happening post-approval that is going to impact patient care and patient involvement in the end.  

But these are not the only ways that it can be impacted, because you’ve got studies on compliance and adherence, which are all patient reported, or measures that are used in clinical practice settings that are helping to improve patient care based on the data being generated.

Are there challenges with translating patient-reported outcomes into clinical and pharmaceutical decisions?

Yes, there’s both benefits and challenges. So, when a PRO measure is being included in a clinical trial for approval, to me that’s a direct link and a benefit, because the moment the drug is getting approved the patient is the one that’s going to be benefitting from a new drug being available, and that added value that PRO data will show. The pharmaceutical manufacturer at that point has already made the decision to include a PRO measure in a clinical study, so that is being pushed forward and really the pharmaceutical decision has been made.

But I feel like patient reported outcomes data needs to be shared more consistently with formularies and coverage decision-makers to make sure that they are showing their understanding, and therefore, making a decision based on that added value of a drug. Until the inclusion of PRO data becomes as standardized and as regular as clinical efficacy, safety, tolerability, or other economic data, we are not going to see that added value. I think the push is towards that, but it’s not there yet. 
 


 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!